Innovating Works

CENTRO ATLANTICO DEL MEDICAMENTO

Inactiva
Oralis: Oralis The first oral human insulin treatment for Type 2 Diabetes Mellitus ORAMED LTD tramitó un H2020: H2020-EIC-SMEInst-2018-2020 Type 2 Diabetes Mellitus (T2DM) affects 415M people globally, 49M of them within Europe. Caring for these individuals costs Europe €181M bil...
2019-11-04 - 2020-03-31 | Financiado
INPACT: Innovative peptides against cancer and pathogenic bacteria with advances in science biopharmaceuti... INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES tramitó un H2020: H2020-MSCA-RISE-2014 INPACT aims at the pre-clinical development of innovative drugs and drug formulations against selected cancers (eg prostate cancer) and path...
2014-11-19 - 2019-01-31 | Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.